ArticleRadiation oncology journal2026
Acute toxicity and quality of life in postoperative prostate cancer patients treated with ultra-hypofractionated pelvic radiation therapy.
Article in Radiation oncology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to report acute toxicity and quality of life (QoL) outcomes in postoperative prostate cancer patients treated with stereotactic body radiation therapy (SBRT) to the prostate bed and pelvic lymph nodes. MATERIALS AND
methodsPatients with prostate cancer who underwent radical prostatectomy and were referred for salvage radiotherapy between January and December 2023 were included. Treatment consisted of 25 Gy to the pelvic nodal areas with a simultaneous integrated boost delivering a total of 30 Gy to the prostate bed, all in 5 fractions, delivered with an empty rectum and comfortably full bladder. Acute gastrointestinal (GI) and genitourinary (GU) toxicities were graded according to Common Terminology Criteria for Adverse Events v5.0. QoL was assessed via phone interview using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-PR25) questionnaire.
resultsA total of 166 patients were treated, of whom 61 had at least 6 months of follow-up. Median age was 65 years, and 77.0% received androgen deprivation therapy. Indications for radiotherapy included biochemical persistence (36.1%), biochemical recurrence (27.9%), local recurrence (21.3%), regional recurrence (6.6%), and combined recurrence (8.2%). All plans met organ-at-risk constraints (mean rectal D1cm³ [dose to the most irradiated 1 cm³] 3,000.7 cGy; bowel D1cm³ 2,457.8 cGy). Acute toxicity data was available for 47 patients. No grade ≥3 acute GI or GU toxicity was observed. Grade 2 GI and GU toxicities occurred in 25.5% and 2.1% of patients, respectively. Among the 62.3% who completed the QoL survey, mean symptom scores were low (urinary, 19.1; bowel, 4.2), and sexual functioning averaged 44.4.
conclusionPostoperative pelvic SBRT demonstrated low acute toxicity and favorable short-term QoL outcomes, supporting its feasibility and safety for further prospective evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.